AstraZeneca To Sell Bengaluru Unit as Part of its Monetization Strategy

AstraZeneca Pharma India is set to sell its 64-acre production facility in North Bengaluru as part of its parent company's strategic review of its global manufacturing and supply network. The deal is expected to generate over ?3,200 crores and aligns with the company's broader land monetization strategy. 

According to property consultants, AstraZeneca has issued a global mandate to select advisors for the sale. "The land, valued at over ?50 crore per acre, is in one of Bengaluru's most sought-after corridors and serves as a key manufacturing site for the pharma major. The property has been intermittently on the market, but previous asking prices were considered too high," said a consultant familiar with the matter. 

AstraZeneca had previously stated that it plans to sell the site as a fully operational manufacturing facility while looking for a buyer who could also serve as a contract manufacturing organization (CMO) for its products, subject to regulatory approvals. 

The Bengaluru facility is one of nine global sites dedicated to designing and conducting clinical trials while ensuring safety, efficacy, and regulatory compliance throughout a product's lifecycle. 

Founded in 1979, AstraZeneca Pharma India is a subsidiary of AstraZeneca Plc, a UK-based company with its Indian headquarters in Bengaluru. 

With rising land prices across India's major cities—Mumbai, Delhi-NCR, Bengaluru, Hyderabad, Chennai, and Pune—corporates, PSUs, and financial institutions are increasingly monetising non-core assets. This trend is fueled by strong demand from developers, increasing real estate valuations, and the need to unlock capital. 

Developers are aggressively acquiring such assets to expand their land banks. Companies like Godrej Properties and Prestige Group have acquired non-core land from corporations and institutions to cater to the growing demand for premium residential and commercial projects. Given the rising land costs and sustained demand, monetization of non-core assets is expected to remain a key corporate strategy in 2025.